Abstract
Abstract
Objective
Despite limited safety and efficacy data, inhaled corticosteroids (ICS) are prescribed to premature infants in the neonatal intensive care unit (NICU). We examined contemporary use and risk factors for ICS use in the NICU.
Study design
Infants <33 weeks gestational age and <1500 gm birth weight discharged from Pediatrix Medical Group NICUs between 2010 and 2020 were included. We evaluated the association between ICS prescription and clinical characteristics using univariable and multivariable logistic regression.
Results
Of 74,123 infants from 308 NICUs, 9253 (12.5%) were prescribed ICS: budesonide, fluticasone, or beclomethasone. Diagnosis of bronchopulmonary dysplasia (BPD), earlier gestational age, male sex, longer mechanical ventilation, oxygen support, and systemic steroids were independent risk factors for ICS prescription.
Conclusions
Use of ICS is common in many NICUs and is associated with a diagnosis of BPD and healthcare utilization. Prospective trials are needed to establish the safety, efficacy, and optimal indication in this vulnerable population.
Funder
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Williams O, Greenough A. Post-natal corticosteroid use. Eur J Pediatr. 2003;162:613–5.
2. Porter KB, Garner SS. Survey of the use of corticosteroids among neonatal intensive care units for the prevention or treatment of bronchopulmonary dysplasia. J Pediatr Pharm Ther. 2005;10:90–9.
3. Maas C, Poets CF, Bassler D. Survey of practices regarding utilization of inhaled steroids in 223 German neonatal units. Neonatology. 2010;98:404–8.
4. Slaughter JL, Stenger MR, Reagan PB, Jadcherla SR. Utilization of inhaled corticosteroids for infants with bronchopulmonary dysplasia. PLoS ONE. 2014;9:e106838.
5. Yao S, Uthaya S, Gale C, Modi N, Battersby C, UK Neonatal Collaborative (UKNC). Postnatal corticosteroid use for prevention or treatment of bronchopulmonary dysplasia in England and Wales 2012–2019: a retrospective population cohort study. BMJ Open. 2022;12:e063835.